Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

SLE - Rituximab in lupus.

Robert Eisenberg1

  • 1Division of Rheumatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA. raemd@mail.med.upenn.edu

Arthritis Research & Therapy
|June 26, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cochlear size variation in a large-scale international multicentre cohort.

Hearing research·2026
Same author

What's in the Bin? A Waste Audit of an Australian Tertiary Ear, Nose and Throat Outpatient Clinic.

ANZ journal of surgery·2026
Same author

Glymphatic Clearance in the Optic Nerve: A Multidomain Electro-Osmostic Model.

Entropy (Basel, Switzerland)·2025
Same author

Potassium Clearance in Optic Nerve: A Multidomain Model.

Frontiers in bioscience (Landmark edition)·2025
Same author

Climate and environmental crisis: effects on ear and hearing health in Australia and for Aboriginal and Torres Strait Islander peoples.

The Medical journal of Australia·2025
Same author

Anatomical and functional studies of vestibular neuroepithelia from patients with Ménière's disease.

Disease models & mechanisms·2025
Same journal

Alterations in systemic and skeletal muscle myostatin regulation are most prominent at disease onset and associate with muscle-related outcomes in idiopathic inflammatory myopathies.

Arthritis research & therapy·2026
Same journal

Plasma proteome differences between giant cell arteritis and polymyalgia rheumatica: a pilot study.

Arthritis research & therapy·2026
Same journal

Elucidating the mechanism of taurine in alleviating osteoarthritis progression based on bioinformatics, machine learning algorithm, and experimental validation.

Arthritis research & therapy·2026
Same journal

Discovery of biomarkers for primary Sj ögren's syndrome based on multi-omics data, construction of diagnostic models, and clinical correlation analysis.

Arthritis research & therapy·2026
Same journal

Identification of distinct subgroups in Chinese patients with Behçet's syndrome via cluster analysis of immune cells and clinical features.

Arthritis research & therapy·2026
Same journal

Artemisinin increases susceptibility to ferroptosis of fibroblast-like synoviocytes in rheumatoid arthritis.

Arthritis research & therapy·2026
See all related articles

Rituximab, a B-cell depleting therapy, shows promise for treating systemic lupus erythematosus (SLE). Further controlled trials are needed to confirm its efficacy and understand B-cell roles in SLE pathogenesis.

Area of Science:

  • Immunology
  • Rheumatology
  • Pharmacology

Background:

  • B cells play a critical role in the pathogenesis of systemic lupus erythematosus (SLE).
  • Current therapeutic strategies for SLE aim to modulate immune responses, but often have limitations.
  • Targeting specific immune cell populations offers a potential avenue for more effective SLE treatment.

Purpose of the Study:

  • To evaluate the potential of rituximab, a monoclonal antibody, as a therapeutic agent for systemic lupus erythematosus (SLE).
  • To explore the role of B cells in the development and progression of SLE.
  • To assess preliminary clinical experiences with rituximab in SLE and other autoimmune conditions.

Main Methods:

  • Rituximab, a chimeric monoclonal antibody, targets the CD20 surface marker found on B cells.

Related Experiment Videos

  • Administration of rituximab leads to the depletion of B cells.
  • Preliminary clinical data from patients with SLE and other autoimmune diseases treated with rituximab were reviewed.

    • Main Results:

    • Preliminary experiences with rituximab in SLE and other autoimmune diseases have been encouraging.
    • Rituximab effectively depletes B cells by targeting CD20.
    • The observed outcomes suggest a potential benefit of B-cell depletion in managing SLE.

    Conclusions:

    • Rituximab demonstrates potential as a therapeutic option for systemic lupus erythematosus (SLE).
    • Further controlled clinical trials are essential to establish the efficacy and safety of rituximab in SLE.
    • Investigating rituximab's effects will provide deeper insights into the pathogenesis of SLE and the role of B cells.